Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours
The Journal of Pathology: Clinical Research · 2023-03 · 9 (2) · 89-99
DOI: 10.1002/cjp2.307 ↗At a glance
Übersichtsarbeit in The Journal of Pathology: Clinical Research, published online on 2022-12-19. Written by Yuehua Li and 4 co-authors. Institution: Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR Ch…. Major MEDLINE topics: Receptor, trkB, Neoplasms. Cited 22 times so far (Crossref); 108 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Science and Technology Commission of Shanghai Municipality.
Abstract (original language)
Tropomyosin receptor kinase B (TrkB), a transmembrane receptor protein, has been found to play a pivotal role in neural development. This protein is encoded by the neurotrophic receptor tyrosine kinase 2 ( NTRK2 ) gene, and its abnormal activation caused by NTRK2 overexpression or fusion can contribute to tumour initiation, progression, and resistance to therapeutics in multiple types of neurogenic tumours. Targeted therapies for this mechanism have been designed and developed in preclinical and clinical studies, including selective TrkB inhibitors and pan‐TRK inhibitors. This review describes the gene structure, biological function, abnormal TrkB activation mechanism, and current‐related targeted therapies in neurogenic tumours.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
ORCID profiles: Zhi-Chao Wang
Funding
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
- Science and Technology Commission of Shanghai Municipality
Cite
APA
Li, Y., Wei, C., Wang, W., Li, Q., & Wang, Z. C. (2023). Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours. The Journal of Pathology: Clinical Research, 9(2), 89-99. https://doi.org/10.1002/cjp2.307
Vancouver
Li Y, Wei C, Wang W, Li Q, Wang ZC. Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours. The Journal of Pathology: Clinical Research. 2023;9(2):89-99. doi:10.1002/cjp2.307
BibTeX
@article{Li2023,
author = {Li, Yuehua and Wei, Chengjiang and Wang, Wei and Li, Qingfeng and Wang, Zhi-Chao},
title = {Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours},
journal = {The Journal of Pathology: Clinical Research},
year = {2023},
volume = {9},
number = {2},
pages = {89--99},
doi = {10.1002/cjp2.307}
}
EUVIMED